NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock

Core Viewpoint - NeuroPace, Inc. has announced a public offering of 6,500,000 shares at a price of $10.00 per share, aiming to raise approximately$65 million before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on February 18, 2025, subject to customary closing conditions [1]. - NeuroPace has granted underwriters a 30-day option to purchase an additional 975,000 shares at the public offering price [1]. - The shares are being offered under a shelf registration statement filed with the SEC, effective since November 22, 2022 [4]. Group 2: Use of Proceeds - Approximately $49.5 million of the net proceeds will be used to repurchase 5,270,845 shares from significant stockholder KCK Ltd. at$9.40 per share [2]. - Remaining proceeds will be allocated for general corporate purposes, including clinical trials, research and development, administrative expenses, debt reduction, and working capital [2]. Group 3: Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of epilepsy patients through its RNS System, which provides personalized, real-time treatment [6].